Category - Developments

Developments

BeyondSpring set to join FTSE Russell 3000 Index

BeyondSpring (NASDAQ:BYSI) will join the FTSE Russell 3000 Index when markets open on July 1, according to a preliminary list of additions. Membership in the Russell 3000 Index, which remains in place for one year...

June 20, 2019

Developments

Akari reports positive initial results from Phase 1/2 atopic keratoconjunctivitis trial

Akari Therapeutics (NASDAQ:AKTX) reported positive data from the first part of its Phase 1/2 study of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC).

June 19, 2019

Developments

Adamas Pharma reports new data from Phase 3 Parkinson’s disease trial

Adamas Pharmaceuticals (NASDAQ:ADMS) reported retrospective data from pooled Phase 3 trials of GOCOVRI in Parkinson’s disease (PD) patients.

June 19, 2019

Developments

FDA accepts Melinta Therapeutics sNDA for pneumonia drug

The FDA has accepted Melinta Therapeutics’ (NASDAQ:MLNT) supplemental NDA (sNDA) for BAXELDA for the treatment of community-acquired bacterial pneumonia (CABP).

June 19, 2019

Developments

Holders of Canopy Growth, Acreage Holdings approve proposed acquisition

Shareholders of Canopy Growth (TSX:WEED; NYSE:CGC) and Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) at separate meetings overwhelmingly approved the proposed acquisition of Acreage by Canopy through a share exchange.

June 19, 2019

Developments

IntelGenx adds Kawartha Centre to Montelukast VersaFilm clinical trial sites

The Kawartha Centre has agreed to participate in IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).

June 19, 2019

Developments

Xeris Pharma reports additional Phase 3 data for ready-to-use glucagon

Xeris Pharmaceuticals (NASDAQ:XERS) reported positive additional results from its global Phase 3 trial of ready-to-use (RTU) liquid glucagon.

June 18, 2019

Developments

G1 Therapeutics reports updated Phase 2 trial results in triple negative breast cancer

G1 Therapeutics (NASDAQ:GTHX) reported preliminary overall survival results from a Phase 2 trial of trilaciclib in women with metastatic triple-negative breast cancer (mTNBC).

June 18, 2019

Developments

Eiger gets FDA breakthrough therapy designation for avexitide

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) avexitide received FDA breakthrough therapy designation for the treatment of post-bariatric hypoglycemia (PBH).

June 18, 2019

Developments

PhaseBio Pharma reports positive initial Phase 2a results for antiplatelet reversal drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported initial results from its Phase 2a trial assessing PB2452’s ability to reverse the effects of the antiplatelet drug, ticagrelor, in subjects 50-to-80 years of age.

June 18, 2019

Category - Developments

Subscribe